280 related articles for article (PubMed ID: 24180232)
1. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
[TBL] [Abstract][Full Text] [Related]
5. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
6. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L
Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379
[TBL] [Abstract][Full Text] [Related]
8. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
11. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Li L; Zhou N; Gong H; Wu J; Lin L; Komuro I; Ge J; Zou Y
Hypertens Res; 2010 Dec; 33(12):1289-97. PubMed ID: 20944638
[TBL] [Abstract][Full Text] [Related]
12. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Nishida Y; Takahashi Y; Nakayama T; Soma M; Asai S
Cardiovasc Diabetol; 2011 Aug; 10():74. PubMed ID: 21827713
[TBL] [Abstract][Full Text] [Related]
14. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
ARB Trialists Collaboration
J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
[TBL] [Abstract][Full Text] [Related]
15. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
Hamada T; Mizuta E; Kondo T; Hirai M; Yamada K; Kato M; Shigemasa C; Yamamoto Y; Ninomiya H; Igawa O; Hisatome I
Arzneimittelforschung; 2010; 60(2):71-5. PubMed ID: 20329654
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
[TBL] [Abstract][Full Text] [Related]
17. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Nixon RM; Müller E; Lowy A; Falvey H
Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
[TBL] [Abstract][Full Text] [Related]
18. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Daikuhara H; Fukunaga K; Ohshima T
Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
[TBL] [Abstract][Full Text] [Related]
19. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
20. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
